Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hirudin and Hirulog

H White1

  • 1Green Lane Hospital, Auckland, New Zealand.

Australian and New Zealand Journal of Medicine
|December 1, 1993
PubMed
Summary
This summary is machine-generated.

This study proposes a trial comparing Hirulog and heparin after streptokinase therapy. Hirulog, a thrombin-specific agent, may improve coronary reperfusion and patency rates in patients receiving streptokinase.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The gut microbiota in adults with cystic fibrosis compared to colorectal cancer.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2023
Same author

Estimation of genetic parameters for feed efficiency traits using random regression models in dairy cattle.

Journal of dairy science·2023
Same author

Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2023
Same author

Can ultrasound strain elastography (USE) improve management of suspicious thyroid nodules measuring <10 mm? A systematic review.

Radiography (London, England : 1995)·2023
Same author

Diabetes is associated with increased burden of gastrointestinal symptoms in adults with cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2023
Same author

Cystic Fibrosis-Related Gut Dysbiosis: A Systematic Review.

Digestive diseases and sciences·2023

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Streptokinase (SK) therapy for myocardial infarction has shown lower patency rates compared to tissue plasminogen activator (t-PA).
  • The effectiveness of anticoagulants following thrombolytic therapy is crucial for improving outcomes.
  • A potent thrombin-specific agent might be more beneficial with SK than with t-PA.

Purpose of the Study:

  • To evaluate the efficacy of Hirulog compared to heparin in patients undergoing thrombolytic therapy with streptokinase.
  • To assess the impact of different Hirulog doses on patient outcomes.
  • To investigate the role of thrombin-specific anticoagulation in improving coronary reperfusion after SK treatment.

Main Methods:

  • A proposed clinical trial involving over 400 patients.

Related Experiment Videos

  • Randomized comparison of Hirulog (at two dose levels) versus heparin.
  • Primary endpoints include angiographic patency and ST-segment monitoring for coronary reperfusion.

    • Main Results:

    • Study is proposed; results are pending.
    • Anticipated to demonstrate differences in patency and reperfusion rates between Hirulog and heparin groups.
    • Potential to establish Hirulog as a superior anticoagulant in this setting.

    Conclusions:

    • The study aims to determine if Hirulog improves outcomes compared to heparin after streptokinase.
    • Findings could support the use of thrombin-specific agents to enhance reperfusion.
    • Results may guide anticoagulant selection in thrombolytic therapy.